

# Journal of Visualized Experiments

## Assessing cellular target engagement by SHP2 (PTPN11) phosphatase inhibitors --Manuscript Draft--

Article Type:	Invited Methods Article - JoVE Produced Video
Manuscript Number:	JoVE61457R2
Full Title:	Assessing cellular target engagement by SHP2 (PTPN11) phosphatase inhibitors
Section/Category:	JoVE Cancer Research
Keywords:	Cellular target engagement assay; CETSA; cellular thermal shift; Protein tyrosine phosphatase; Src-homology 2 domain-containing phosphatase; SHP2; PTPN11; allosteric inhibitor; small molecule; anticancer drug; drug discovery; protein drug interaction
Corresponding Author:	Lutz Tautz Sanford Burnham Prebys Medical Discovery Institute La Jolla, CA UNITED STATES
Corresponding Author's Institution:	Sanford Burnham Prebys Medical Discovery Institute
Corresponding Author E-Mail:	tautz@sbpdiscovery.org
Order of Authors:	Lester J. Lambert Celeste Romero Douglas J. Sheffler Maria Celeridad Nicholas D. P. Cosford Lutz Tautz
Additional Information:	
Question	Response
Please indicate whether this article will be Standard Access or Open Access.	Standard Access (US\$2,400)
Please indicate the <b>city, state/province, and country</b> where this article will be <b>filmed</b> . Please do not use abbreviations.	La Jolla, California, United States

**TITLE:****Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors****AUTHORS AND AFFILIATIONS:**

Lester J. Lambert<sup>1</sup>, Celeste Romero<sup>1</sup>, Douglas J. Sheffler<sup>1</sup>, Maria Celeridad<sup>1</sup>, Nicholas D. P. Cosford<sup>1</sup>, Lutz Tautz<sup>1</sup>

<sup>1</sup>Cancer Metabolism & Signaling Networks Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.

Corresponding author:

Lutz Tautz (tautz@SBPdiscovery.org)

Email addresses of co-authors:

Lester J. Lambert (llambert@SBPdiscovery.org)

Celeste Romero (Celeste.Romero@UTSouthwestern.edu)

Douglas J. Sheffler (dsheffler@SBPdiscovery.org)

Maria Celeridad (mceleridad@SBPdiscovery.org)

Nicholas D. P. Cosford (ncosford@SBPdiscovery.org)

**KEYWORDS:**

cellular target engagement assay, cellular thermal shift, protein tyrosine phosphatase, Src-homology 2 domain-containing phosphatase, SHP2, PTPN11, allosteric inhibitor, small molecule, anticancer drug, drug discovery, protein drug interaction

**SUMMARY:**

The ability to assess target engagement by candidate inhibitors in intact cells is crucial for drug discovery. This protocol describes a 384 well format cellular thermal shift assay that reliably detects cellular target engagement of inhibitors targeting either wild-type SHP2 or its oncogenic variants.

**ABSTRACT:**

The Src-homology 2 (SH2) domain-containing phosphatase 2 (SHP2), encoded by the *PTPN11* proto-oncogene, is a key mediator of receptor tyrosine kinase (RTK)-driven cell signaling, promoting cell survival and proliferation. In addition, SHP2 is recruited by immune check point receptors to inhibit B and T cell activation. Aberrant SHP2 function has been implicated in the development, progression, and metastasis of many cancers. Indeed, small molecule SHP2 inhibitors have recently entered clinical trials for the treatment of solid tumors with Ras/Raf/ERK pathway activation, including tumors with some oncogenic Ras mutations. However, the current class of SHP2 inhibitors is not effective against the SHP2 oncogenic variants that occur frequently in leukemias, and the development of specific small molecules that target oncogenic SHP2 is the subject of current research. A common problem with most drug discovery campaigns, with those involving cytosolic proteins like SHP2, is that the primary assays that drive chemical discovery are often in vitro assays that do not report the cellular target engagement of candidate compounds.

To provide a platform for measuring cellular target engagement, we developed both wild-type and mutant SHP2 cellular thermal shift assays. These assays reliably detect target engagement of SHP2 inhibitors in cells. Here, we provide a comprehensive protocol of this assay, which provides a valuable tool for the assessment and characterization of SHP2 inhibitors.

## INTRODUCTION:

Tyrosine phosphorylation plays an important role in signal transduction in cells<sup>1,2</sup>. This post-translational modification is catalyzed by protein tyrosine kinases (PTKs) and reversed by protein tyrosine phosphatases (PTPs). Therefore, aberrant PTK or PTP function leads to many inherited or acquired human diseases<sup>3-6</sup>. The Src-homology 2 (SH2) domain-containing phosphatase 2 (SHP2) is a widely expressed non-receptor type PTP encoded by the proto-oncogene *PTPN11*<sup>7</sup> and is a key regulator of numerous physiological processes that involve signal transduction by activation of the Ras/Raf/ERK, PI3K/Akt, or JAK/STAT signaling pathways<sup>8</sup>. Normally, SHP2 activity is tightly regulated in order to prevent aberrant signaling. Under basal conditions SHP2 is autoinhibited by its N-terminal SH2 domain, which blocks access to the active site within the catalytic phosphatase domain (**Figure 1A**)<sup>9,10</sup>. Upon cell activation, tyrosine phosphorylated binding proteins recruit SHP2, causing it to adopt its active conformation, in which the active site is now accessible to its substrates. In many cancers SHP2 activity is elevated. Somatic gain-of-function (GOF) mutations in *PTPN11* have been identified mainly in leukemias and prevent binding of the N-SH2 domain to the phosphatase domain, resulting in constitutively active SHP2 (**Figure 1B**)<sup>11</sup>. Germline GOF mutations in *PTPN11* are responsible for ~50% of cases of Noonan syndrome, a developmental disorder with an increased risk of malignancy<sup>12</sup>. In solid tumors, where *PTPN11* mutations are rare, greater levels of phosphorylated binding proteins lead to enhanced SHP2 activity (**Figure 1C**). SHP2 is also important for immune checkpoint signaling, as checkpoint receptors such as BTLA or PD-1 recruit SHP2 to dephosphorylate key signaling molecules, preventing immune cell activation<sup>13-15</sup>.

Targeting PTPs with small molecules has been a challenge, because the active site of PTPs is highly conserved and highly charged; inhibitors that target the active site are often potent, but exhibit poor selectivity and oral bioavailability<sup>16-22</sup>. Indeed, many reported SHP2 inhibitors suffer from poor selectivity and lack of efficacy in cells<sup>23</sup>. Recently, allosteric inhibitors of SHP2 with good potency and excellent selectivity have been reported (e.g., SHP099<sup>24</sup> and RMC-4550<sup>25</sup>) and have sparked renewed interest in SHP2 inhibitors. Compounds based on SHP099 and RMC-4550 are currently in phase I clinical trials to treat solid tumors with receptor tyrosine kinase (RTK) pathway activation<sup>26,27</sup>. While groundbreaking, these compounds are ineffective against many of the SHP2 oncogenic mutants that drive leukemogenesis in a significant number of blood cancer patients<sup>28-30</sup>. This lack of potency of SHP099-like compounds toward the SHP2 oncogenic variants stems from their unique allosteric mechanism, as they inhibit SHP2 activity by binding and stabilizing the inactive, closed conformation, which is disrupted in SHP2 mutants. Further, based on a recent report<sup>31</sup>, adaptive resistance mechanisms in patients treated with SHP099-like inhibitors are quite conceivable. Consequently, the development of next generation SHP2 inhibitors that target its active, open state is a subject of intense research.

The characterization of novel SHP2 inhibitors in cells is an essential aspect of the lead

optimization process. Critically, proven target engagement of the inhibitor under physiological conditions provides an additional level of confidence that resources for medicinal chemistry are efficiently deployed on compounds with promising cellular efficacy. In the past, several methods to assess the binding of small molecule inhibitors to their targets have been developed, primarily for protein kinases<sup>32</sup>. To develop a SHP2 cellular target engagement assay, we utilized a cellular thermal shift assay<sup>33</sup>. This assay, similar to the in vitro thermal shift (PTS) assay for proteins<sup>34</sup>, monitors the target protein thermal stability, which is typically altered by the binding of small molecules. The original assay is a low throughput assay that utilizes antibodies to quantify target protein levels. Alternatively, we chose a recently reported variant of the thermal shift assay that utilizes a  $\beta$ -galactosidase enzyme fragment complementation (EFC) assay (**Figure 2**)<sup>35</sup>. For these experiments, the protein of interest is expressed in cells as an N- or C-terminal fusion protein carrying an enhanced ProLabel tag (ePL, a 42 amino acid fragment of  $\beta$ -galactosidase). Cells are then transferred to 384 well PCR compatible plates and incubated with compounds of interest. A thermocycler is utilized to apply a temperature gradient to the cells, whose proteins will denature and aggregate as the temperature increases based upon their thermal stability. The ability of a candidate compound to bind and stabilize the protein of interest will result in an increased thermal stability of that protein. Therefore, following the lysis of the cells, those tagged proteins that have been stabilized by a candidate compound will remain in solution at higher temperatures than tagged proteins of cells incubated with vehicle control. Reporter enzyme acceptor (EA) is able to complement the soluble ePL-tagged proteins, resulting in detectable  $\beta$ -galactosidase activity using a luminescence substrate.

We recently developed a robust cellular thermal shift assay for wild-type SHP2 (SHP2-WT) and a frequent SHP2 oncogenic variant (SHP2-E76K) in a miniaturized 384-well format<sup>36</sup>. Here, we report a detailed protocol of this assay, which reliably detects target engagement by SHP2 inhibitors in cells and demonstrates a high degree of correlation between inhibitor potency and cellular thermal shift data. The general assay workflow is illustrated in **Figure 3**. Our platform uses N-terminally tagged full-length ePL-SHP2 fusion proteins. For the generation of the corresponding pICP-ePL-N-SHP2-WT and pICP-ePL-N-SHP2-E76K expression plasmids, please refer to our recent publication<sup>36</sup>. This assay can be performed using a thermal gradient to establish SHP2 thermal profiles and determine SHP2 melting temperatures in the presence or absence of inhibitor. Once thermal profiles have been established, it can also be performed under isothermal conditions, allowing inhibitor dose-response assessment. Both types of experiments are described below.

## **PROTOCOL:**

### **1. Preparation of cell culture and reagents**

1.1. Formulate a 500 mL bottle of growth media with 10% fetal bovine serum, 1x antibiotic/antimycotic, 20 mM HEPES, and 1 mM sodium pyruvate. Store at 4 °C.

1.2. Thaw cellular thermal shift reagents (EA reagent, lysis buffer, and substrate) from frozen original stock bottles.

133  
134 1.3. Dispense reagents and buffer as 2 mL aliquots and store at -20 °C.

135  
136 NOTE: Avoid freeze/thaw for reproducibility and use only that volume of reagent required for the  
137 assay procedure.

## 138 139 **2. Growth and maintenance of HEK293T cells**

140  
141 2.1. Obtain low passage adherent HEK293T cells from cryo storage.

142  
143 2.2. Maintain HEK293T cells in growth media at 37 °C, 5% CO<sub>2</sub>.

144  
145 2.3. Split cells every 4 days in a 1:14 ratio.

146  
147 NOTE: For best performance, HEK293T cells are not allowed to passage greater than 25 times.

## 148 149 **3. HEK293T cell preparation for transient transfection**

150  
151 3.1. Detach HEK293T cells from 16 mL plates using 3 mL of the cell detachment reagent.

152  
153 3.2. Dilute with 12 mL of growth media. Collect cells by centrifugation at 1,400 x g for 4 min.

154  
155 3.3. Resuspend the pellet in 10 mL growth media. Measure the concentration and viability of cells  
156 using trypan blue and a cell counter.

157  
158 3.4. Plate  $7.0 \times 10^5$  exponentially growing HEK293T cells per well in a 6 well cell culture plate  
159 approximately 24 h before transfection.

160  
161 NOTE: Reserve one well for each plasmid to be transfected.

162  
163 3.5. Incubate for 24 h at 37 °C, 5% CO<sub>2</sub>.

## 164 165 **4. Transfection of HEK293T cells**

166  
167 4.1. From a purified plasmid stock of pICP-ePL-N-SHP2-WT or pICP-ePL-N-SHP2-E76K (~200  
168 ng/μL) dilute 2 μg of plasmid DNA into 200 μL of transfection buffer.

169  
170 4.2. Vortex for 10 s and centrifuge at 1,400 x g for 4 min.

171  
172 4.3. Add 4 μL of transfection reagent to the diluted DNA. Vortex for 10 s and centrifuge at 1,400  
173 x g for 4 min.

174  
175 4.4. Incubate at 23 °C for 10 min.

176

4.5. Remove the 6 well plate containing growing HEK293T cells from incubator. Add the transfection mix to the attached cells in the 6-well plate. Incubate for 24 h at 37 °C, 5% CO<sub>2</sub>.

## **5. Preparation of assay plates**

5.1. Prepare 10 mM stock solutions in DMSO of compounds to be tested.

5.2. Dispense inhibitor solutions into a 384 well low dead volume source plate for immediate use.

5.3. Spot the desired volume of inhibitors or vehicle (DMSO) using a liquid handler into 384 well real-time PCR plates at a target final volume of less than 0.5% DMSO (v/v). Seal the plate using a plate sealer with inert gas purging.

NOTE: For inhibitor dose-response assays, make sure to backfill DMSO accordingly so that equal amounts of DMSO are used for each inhibitor concentration. For best results, store plates at 23 °C and use plates within 24 h.

## **6. Transfected cell detachment and preparation**

6.1. Preincubate growth media and cell detachment reagent in a 37 °C water bath. Remove transfected cells from the incubator. Gently aspirate media from the wells of the plate.

NOTE: Use a new aspirator for every well that contains a different transfected plasmid.

6.2. Add 0.3 mL of the cell detachment reagent. Gently rock the plate back and forth to thoroughly cover the surface of the plate bottom. Incubate at 23 °C for 2 min.

6.3. Add 1 mL of growth media to each well. Gently pipette media and cells in the well and transfer to a 15 mL Falcon centrifuge tube. Collect cells by centrifugation at 1,400 x g for 4 min.

6.4. Gently but thoroughly aspirate off the media.

NOTE: Residual phenol red in the cell detachment reagent can interfere with the assay.

6.5. Carefully resuspend cell pellet in 2 mL of growth media. Measure the concentration and viability of cells using trypan blue and a cell counter.

NOTE: Cell viability should be > 90% for best results.

6.6. Dilute cells to a concentration of 125 cells/μL. For example, for a 5 μL assay this is ~625 cells/μL. For optimal viability keep cells in suspension for no more than 2 h.

## **7. Incubation of cells with SHP2 inhibitors**

221 7.1. Dispense cells into a sterile single channel solution trough.

222  
223 7.2. Centrifuge 384 well real-time PCR plate that has been pre-prepared by SHP2 inhibitor  
224 deposition at 2,500 x *g* for 5 min at 23 °C.

225  
226 7.3. Remove seal from the compound plate. Using a 125 µL multichannel pipette, add 5 µL of the  
227 diluted cells to desired wells.

228  
229 7.4. Centrifuge the plate at 42 x *g* for 30 s without a lid on the plate. Attach a lid seal to the plate  
230 after the plate is spun down and incubate the assay plate at 37 °C, 5% CO<sub>2</sub> for 1 h.

## 231 232 **8. Preparation of chemiluminescent reagent master mix**

233  
234 8.1. Remove the necessary quantity of detection reagents (EA reagent, lysis buffer, and substrate)  
235 from -20 °C storage after plating cells. Thaw reagents at 23 °C.

236  
237 NOTE: For convenience in transfer, prepare a volume that is 1.5x the total volume of cells that  
238 have been deposited to the plate. Do not reuse reagents after use.

239  
240 8.2. Prepare a master mix of the reagents using condition EA-10, which consists of component  
241 and volume fraction as follows: EA reagent (0.17), lysis buffer (0.17), substrate (0.67).

242  
243 NOTE: Reagent ratios are based on optimization experiments performed as specified in the  
244 supplier's manual.

## 245 246 **9. Isothermal or thermal profile gradient heat pulse**

247  
248 9.1. Program the gradient capable thermocycler for the delivery of heat pulse.

249  
250 9.1.1. For thermal profile gradient experiments, preprogram the thermocycler with the following  
251 example specifications:

252  
253 9.1.2. Heat pulse: 3 min desired melting temperature (vertical or horizontal gradient +/- 15 °C;  
254 example 38-68 °C spread across 24 wells yields temperature increments of 1.25 °C).  
255 Equilibration recovery step: 3 min 20 °C with ramp speed = 1 °C/s

256  
257 9.2.1. For isothermal experiments set up the protocol set up as follows:

258  
259 9.2.2. Heat pulse: 3 min 55 °C. Equilibration recovery step: 3 min 20 °C with ramp speed = 1°C/s

260  
261 NOTE: For increased reproducibility, as it can be difficult to place the plate precisely at the time  
262 the thermocycler reaches its desired temperature, set up the program to count down 15 s before  
263 beginning the 3 min pulse. For the thermocycler used in this experiment see **Table of Materials**,  
264 the lid is kept up during the heat pulse.

## 10. Lysis detection and measurement

10.1. Supplement assay plates with lysis detection master mix by addition of equal volumes (5  $\mu$ L) to each well to be analyzed using a multichannel pipette.

10.2. Centrifuge the plate 42 x *g* for 30 s. Store at 23 °C in darkness for 30-60 min.

10.3. Measure chemiluminescence using a microplate reader capable of detecting luminescence in 384-well format. Perform luminescence measurement with the plate type and integration time optimized (integration time 1000 ms, settle time 0 s). Measure values as counts/s and output for further analysis.

## 11. Data analysis

11.1. Analyze the luminescence data using a scientific 2D graphing and statistics software.

11.2. Generate thermal profiles by analyzing the normalized luminescence data (normalized to the vehicle control) using nonlinear regression and a Boltzmann sigmoidal model.

NOTE: In thermal profile experiments, the calculated  $V_{50}$ , the temperature that is the halfway point between bottom and top of the curve, defines the melting temperature of SHP2. In isothermal experiments,  $EC_{50}$  defines the concentration of the inhibitor that gives half-maximal response.

### REPRESENTATIVE RESULTS:

The thermal gradient experiment for SHP2-WT resulted in a sigmoidal cellular thermal profile with a narrow melting transition that is typical and consistent for a folded protein (**Figure 4A**). SHP2 consists of three independent domains: two SH2 domains and the catalytic domain (**Figure 1**). In the autoinhibited closed conformation these domains self-associate; the melting transition that was observed in the thermal profile experiment presumably reflected this state in the cell. Incubation of SHP2-WT with the allosteric inhibitor SHP099 at 10  $\mu$ M stabilized the SHP2-WT thermal profile to a significant and measurable degree (**Figure 4A**). This is reflective of the known binding mode of SHP099-like inhibitors which act as "molecular glue"<sup>37</sup> between the regulatory binding SH2 domains and the catalytic subunit. Importantly, our cellular thermal shift assay confirmed that SHP099 can penetrate the cell and bind to the labeled SHP2-WT. The stabilization of SHP2 also tracked with the potency of SHP099-like allosteric compounds. At 10  $\mu$ M, the more potent RMC-4550 (reported  $IC_{50}$  = 0.6 nM) produced a greater degree of stabilization than SHP099 (reported  $IC_{50}$  = 70 nM) for SHP2-WT (**Figure 4B**).

We observe a different behavior in the thermal profile of the target engagement assay with the oncogenic mutant SHP2-E76K (**Figure 4C**). The thermal profile for SHP2-E76K has a melting transition that is less narrow, reflecting the destabilization imparted on the tertiary structure of SHP2 by the E76K mutation, which is known to disrupt interactions between the SH2 domains

and the catalytic subunit. Therefore, the observed melting temperature was reduced compared to the WT protein. Importantly, when incubated with the allosteric inhibitor SHP099 at 10  $\mu$ M, only marginal thermal stabilization was observed, consistent with the known properties of SHP099 and similar inhibitors<sup>28-30</sup>.

The expression level of the ePL-tagged protein to be probed can dramatically influence the signal intensity. Shown (**Figure 4D**) are thermal profiles for transient and stably integrated SHP2-WT cells under identical assay conditions. Normalization of these disparate curves affords comparable thermal profiles (**Figure 4E**), indicating the wide range of the EFC detection system. It is important to note that we have employed both transient transfection and stable integration SHP2 expressing cells with comparable results. For the generation of stable cell lines it should be noted that HEK293 cells rather than HEK293T cells should be used, as HEK293T cells already have a neomycin resistance marker that would prevent selection of cells with integrated pICP-ePL-N-SHP2 plasmid, which contains a neomycin/kanamycin resistance gene for selection in mammalian cells.

To obtain inhibitor dose-response measurements, one can perform compound titrations on cells under isothermal conditions. To do so, we suggest to first determine the temperature optimum for these measurements. Taking advantage of the thermocycler ability to produce thermal gradients on the "short" axis of a 384-well plate, a series of isothermal titrations can be performed on a single plate. **Figure 5A** shows representative results of this optimization for SHP2-WT using a limited five-point dose-response of RMC-4550. Temperatures that were too low to denature the protein produced a high signal that was independent of the drug. Similarly, temperatures that were too high afforded little capacity for the compound to stabilize the protein. However, at an optimal temperature, as determined by this experiment, an isothermal titration using a full 10-point dose-response yielded a useful EC<sub>50</sub> for RMC-4550 (**Figure 5B**). In addition to the representative data shown here, we have determined that experiments using optimized isothermal conditions can be employed to efficiently screen novel SHP2 inhibitors for their ability to cross cell membranes and engage their target in cells<sup>36</sup>.

## FIGURES AND TABLE LEGENDS:

**Figure 1: Regulation of SHP2 activity.** (A) SHP2 activity is tightly regulated in normal cells. Under basal conditions, its N-terminal SH2 domain occludes the active site within the phosphatase (PTP) domain, resulting in autoinhibition. RTK growth factor and cytokine stimulation leads to tyrosine phosphorylation of adapter proteins, which then bind to the SH2 domains, causing a conformational change whereby the SHP2 active site becomes accessible to its substrates. (B) Somatic SHP2 mutations, frequently found in leukemias, are located at the interface between the N-SH2 and phosphatase domains and prevent SHP2 from adopting the closed, autoinhibited conformation, resulting in a constitutively active phosphatase. (C) In solid tumors, amplification or overexpression of growth factors, RTKs, or scaffolding adapters result in aberrant activation of SHP2.

**Figure 2: SHP2 cellular thermal shift principles.** Our cellular target engagement assay is based on a  $\beta$ -galactosidase ( $\beta$ -gal) enzyme fragment complementation (EFC) assay. Cells (HEK293T), expressing full-length SHP2 with an ePL fusion tag (42 amino acid fragment of  $\beta$ -gal), are treated with a probe compound and are subjected to a short heat pulse that causes SHP2 to denature and form inaccessible insoluble aggregates, rendering the ePL tag inaccessible. Specific binding of the probe compound to SHP2 can enhance its thermal stability. Thermal stabilization provides more soluble target protein with the ePL tag for complementation in the reporter enzyme chemiluminescence system. Aggregates result in reduced complementation and luminescence. This figure has been modified from ref.<sup>36</sup>.

**Figure 3: Miniaturized SHP2 equipment workflow.** Routine performance of the assay makes use of the equipment indicated. Assay plates are prepared using an acoustic liquid handler that delivers nanoliter volumes of compounds. Cell transfer can be performed manually, using a multichannel pipette, or by using an automatic liquid dispenser. Heat pulse denaturation uses a thermocycler that can deliver thermal gradients to a 384 well plate. A microplate reader is used to detect the  $\beta$ -gal EFC assay chemiluminescence.

**Figure 4: Cellular target engagement of allosteric SHP2 inhibitors with SHP2-WT and SHP2-E76K proteins.** (A) The SHP2-WT protein in the presence of vehicle (DMSO, red) produced a well-behaved cellular thermal profile with a narrow melting transition consistent with a folded protein in the autoinhibited state. Incubation of SHP2-WT expressing cells with 10  $\mu$ M SHP099 stabilized the protein in the bound state (blue). (B) Cellular target engagement thermal profiles of SHP2-WT in the absence (red) or presence of the SHP099-like allosteric inhibitor RMC-4550 (10  $\mu$ M, blue). RMC-4550 produced an increased cellular stabilization of SHP2-WT than that observed for SHP099. This increased target engagement tracks with its greater biochemical potency. (C) The SHP2-E76K mutant had a less pronounced melting curve consistent with a state that is largely in the "open" active form (red). SHP099 at 10  $\mu$ M only marginally increased the SHP2-E76K melting temperature (blue), which is in agreement with biochemical inhibition and cellular efficacy data. (D) The observed chemiluminescence signal corresponds to the expression level of ePL-SHP2. Compared to transiently transfected HEK293T cells, HEK293 cells in which the ePL tagged SHP2-WT was stably integrated into the genome, had a reduced level of ePL-SHP2 expression. Consequently, the raw unnormalized chemiluminescence thermal profiles showed a greatly reduced luminescence signal for the stably expressing HEK293 cells (blue) compared to the transiently transfected HEK293 cells (red). (E) Normalization of the raw chemiluminescence data for stable (HEK293) and transiently transfected (HEK293T) produced comparable thermal profiles, showing the sensitivity of the measurements. Data points and error bars ( $\pm$ SD) represent duplicate measurements.

**Figure 5: Cellular target engagement isothermal dose-response assay for SHP2-WT.** (A) In order to establish optimal isothermal conditions to evaluate the dose-dependent target engagement of SHP2 inhibitors, a thermal gradient across the short axis of a 384 well plate is first performed. This allows efficient assessment of five-point dose-responses of inhibitors (RMC-4550; 0.08–10  $\mu$ M) to identify the optimal temperature. (B) A full cellular isothermal dose-response (10-point)

for RMC-4550 at an optimal temperature of 56°C. The EC<sub>50</sub> at this temperature is indicated. Data points and error bars (± SD) represent quadruplicate measurements.

## **DISCUSSION:**

We have presented a target engagement assay that can confirm direct binding of small molecules to the SHP2 phosphatase in cells. The assay can discriminate between low and high affinity inhibitors and, importantly, confirm a lack of potency by the allosteric inhibitors of the SHP099-type for the GOF oncogenic SHP2-E76K mutant. A strength of this miniaturized assay is its ability to be integrated into a SHP2 inhibitor screening campaign. The ability of the assay to confirm intracellular binding to SHP2 by unknown chemical matter is an important capacity to assure that screening resources can be efficiently deployed. Overall, the miniaturized protocol is robust and reliable.

A critical aspect of the assay is timing; best results are obtained 24 h after transfection of the HEK293T cells. The SHP2-WT and SHP2-E76K proteins do not appear to be toxic; however, long-term high expression could reduce the sensitivity of the experiment and would require re-optimization. Careful handling of cells to detach and prepare them for the assay is an additional critical consideration. However, standard cell culture methods are sufficient to produce high-quality data. We have incorporated a number of centrifugation steps into the workflow because of the small volumes utilized in this assay. These steps have the purpose to assure quantitative mixing, so adherence to the acceleration and time of centrifugation is recommended. Of note, the assay reagents can suffer after poor handling. Therefore, we recommend that they be aliquoted and stored frozen until use.

The most commonly encountered problem in the performance of this assay is an erratic (noisy) or low luminescence signal. To determine the source of this problem, it is routine to perform Western blot analysis on transfected HEK293T cells using anti-ePL antibodies to assure a reliable expression level of SHP2-WT and SHP2-E76K. We have obtained best results using the reagent protocol outlined in step 4. Once transfection conditions are established, and a single stock of SHP2 expression plasmid is obtained, we have found the assay to be highly reliable.

Assay development requires optimization of the chemiluminescent signal window to assure reliable results are obtained. To optimize the assay window, the most significant parameter is the formulation of the detection reagent master mix as described in the supplier's manual. This optimization is performed by systematically changing the EA reagent to substrate ratio in the master mix, while the lysis buffer component is held constant (four different conditions are usually sufficient for this measurement). A condition with zero EA reagent serves as the background. The assay is performed as described above, and the ratio of the observed signal to background (S/B) is calculated. Reliable results are obtained when the S/B ratio is >50. Master mix conditions that result in extraordinarily high signal are to be avoided, as they will result in depletion of the chemiluminescence substrate.

A potential limitation of the assay is its sensitivity. In our experience, inhibitors with at least a low micromolar potency in SHP2 phosphatase inhibition assays are required for producing

measurable effects in the cellular thermal shift assay. As a general guideline, we suggest to first assess candidate compounds in in vitro PTS assays using recombinant SHP2<sup>36</sup>. Based on results from our ongoing SHP2 inhibitor discovery program, a compounds ability to shift the SHP2 melting temperature in vitro tracks well with its capacity to stabilize (or sometimes destabilize) the SHP2 protein in cells. Interestingly, the relative stabilization of SHP2-WT by SHP099-like allosteric inhibitors appears to be greater than that caused by equally potent SHP2 active site-directed inhibitors, likely reflecting the ability of the allosteric inhibitors to effectively stabilize a physiologically relevant conformation of the SHP2-WT protein.

In addition to the SHP2 phosphatase, we have gained experience in developing cellular target engagement assays for other phosphatases and kinases. A primary consideration with a different protein target is to utilize a combination of positive and negative control experiments to establish the validity of the assay, before fully committing resources to the interpretation of ligand binding data. Further, there are other technologies available for assessing cellular target engagement. We have explored a number of alternatives for the SHP2 phosphatase but have found this assay to be highly useful in our efforts. Finally, this assay is independent of SHP2 enzymatic activity and therefore allows for the evaluation and optimization of small molecules without regard to their binding mode.

#### ACKNOWLEDGMENTS:

This work was supported by National Institutes of Health Grant 1R21CA195422 (to L. T.), Epstein Family Foundation Award (to N. D. P. C.), and NCI Cancer Center Support Grant P30CA030199. Additionally, this project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, under Chemical Biology Consortium Contract No. HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

#### DISCLOSURES:

The authors declare that they have no conflicts of interest with the contents of this article.

#### REFERENCES:

1. Hunter, T. Tyrosine phosphorylation: thirty years and counting. *Current Opinion in Cell Biology*. **21** (2), 140-146 (2009).
2. Alonso, A. et al. Protein tyrosine phosphatases in the human genome. *Cell*. **117** (6), 699-711 (2004).
3. Cohen, P. Protein kinases—the major drug targets of the twenty-first century? *Nature Reviews Drug Discovery*. **1** (4), 309 (2002).
4. Ferguson, F. M., Gray, N. S. Kinase inhibitors: the road ahead. *Nature Reviews: Drug Discovery*. **17** (5), 353-377 (2018).
5. Stanford, S. M., Bottini, N. Targeting Tyrosine Phosphatases: Time to End the Stigma.

484 *Trends in Pharmacological Sciences*. **38** (6), 524-540 (2017).

485 6. Tonks, N. Protein tyrosine phosphatases--from housekeeping enzymes to master  
486 regulators of signal transduction. *FEBS Journal*. **280** (2), 346-378 (2013).

487 7. Chan, R., Feng, G. PTPN11 is the first identified proto-oncogene that encodes a tyrosine  
488 phosphatase. *Blood*. **109** (3), 862-867 (2007).

489 8. Chan, G., Kalaitzidis, D., Neel, B. The tyrosine phosphatase Shp2 (PTPN11) in cancer.  
490 *Cancer Metastasis Rev*. **27** (2), 179-192 (2008).

491 9. Hof, P., Pluskey, S., Dhe-Paganon, S., Eck, M., Shoelson, S. Crystal structure of the  
492 tyrosine phosphatase SHP-2. *Cell*. **92** (4), 441-450 (1998).

493 10. Barford, D., Neel, B. Revealing mechanisms for SH2 domain mediated regulation of the  
494 protein tyrosine phosphatase SHP-2. *Structure*. **6** (3), 249-254 (1998).

495 11. Neel, B. G., Chan, G., Dhanji, S. in *Handbook of Cell Signaling (Second Edition)* Vol. 2  
496 Pages 771-809 Amsterdam: Academic Press (2010).

497 12. Tartaglia, M. et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase  
498 SHP-2, cause Noonan syndrome. *Nature Genetics*. **29** (4), 465-468 (2001).

499 13. Yokosuka, T. et al. Programmed cell death 1 forms negative costimulatory microclusters  
500 that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. *Journal of*  
501 *Experimental Medicine*. **209** (6), 1201-1217 (2012).

502 14. Okazaki, T., Maeda, A., Nishimura, H., Kurosaki, T., Honjo, T. PD-1 immunoreceptor  
503 inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing  
504 tyrosine phosphatase 2 to phosphotyrosine. *Proceedings of the National Academy of Sciences*  
505 *U. S. A.* **98** (24), 13866-13871 (2001).

506 15. Watanabe, N. et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4  
507 and PD-1. *Nature Immunology*. **4** (7), 670-679 (2003).

508 16. Bialy, L., Waldmann, H. Inhibitors of protein tyrosine phosphatases: next-generation  
509 drugs? *Angewandte Chemie International Edition England*. **44** (25), 3814-3839 (2005).

510 17. Kumar, S., Liang, F., Lawrence, D., Zhang, Z. Small molecule approach to studying protein  
511 tyrosine phosphatase. *Methods*. **35** (1), 9-21 (2005).

512 18. Tautz, L., Pellecchia, M., Mustelin, T. Targeting the PTPome in human disease. *Expert*  
513 *Opinion in Therapeutics Targets*. **10** (1), 157-177 (2006).

514 19. Tautz, L., Mustelin, T. Strategies for developing protein tyrosine phosphatase inhibitors.  
515 *Methods*. **42** (3), 250-260 (2007).

516 20. Vintonyak, V., Antonchick, A., Rauh, D. Waldmann, H. The therapeutic potential of  
517 phosphatase inhibitors. *Current Opinion in Chemical Biology*. **13** (3), 272-283 (2009).

518 21. Barr, A. Protein tyrosine phosphatases as drug targets: strategies and challenges of  
519 inhibitor development. *Future Medicinal Chemistry*. **2** (10), 1563-1576 (2010).

520 22. He, R., Zeng, L., He, Y., Zhang, S., Zhang, Z. Small molecule tools for functional  
521 interrogation of protein tyrosine phosphatases. *FEBS Journal*. **280**, 731-750 (2012).

522 23. Tsutsumi, R., Ran, H., Neel, B. G. Off-target inhibition by active site-targeting SHP2  
523 inhibitors. *FEBS Open Biology*. **8** (9), 1405-1411 (2018).

524 24. Chen, Y. N. et al. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by  
525 receptor tyrosine kinases. *Nature*. **535** (7610), 148-152 (2016).


526 25. Nichols, R. J. et al. RAS nucleotide cycling underlies the SHP2 phosphatase dependence  
527 of mutant BRAF-, NF1- and RAS-driven cancers. *Nature Cell Biology*. **20** (9), 1064-1073 (2018).

26. *Clinical Trial NCT03114319*,  
<<https://clinicaltrials.gov/ct2/show/NCT03114319?term=NCT03114319&rank=1>> (2019).
27. *Clinical Trial NCT03634982*,  
<<https://clinicaltrials.gov/ct2/show/NCT03634982?term=NCT03634982&rank=1>> (2019).
28. Sun, X. et al. Selective inhibition of leukemia-associated SHP2(E69K) mutant by the allosteric SHP2 inhibitor SHP099. *Leukemia*. **32** (5), 1246-1249 (2018).
29. LaRoche, J. R. et al. Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition. *Nature Communication*. **9** (1), 4508 (2018).
30. Padua, R. A. P. et al. Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2. *Nature Communication*. **9** (1), 4507 (2018).
31. Lu, H. et al. Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR. *Oncotarget*. **11** (3), 265-281 (2020).
32. Smyth, L. A., Collins, I. Measuring and interpreting the selectivity of protein kinase inhibitors. *Journal of Chemical Biology*. **2** (3), 131-151 (2009).
33. Martinez Molina, D. et al. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. *Science*. **341** (6141), 84-87 (2013).
34. Ericsson, U., Hallberg, B., Detitta, G., Dekker, N., Nordlund, P. Thermofluor-based high-throughput stability optimization of proteins for structural studies. *Analytical Biochemistry*. **357** (2), 289-298 (2006).
35. McNulty, D. E. et al. A High-Throughput Dose-Response Cellular Thermal Shift Assay for Rapid Screening of Drug Target Engagement in Living Cells, Exemplified Using SMYD3 and IDO1. *SLAS Discovery*. **23** (1), 34-46 (2018).
36. Romero, C. et al. A cellular target engagement assay for the characterization of SHP2 (PTPN11) phosphatase inhibitors. *Journal of Biological Chemistry*. **295** (9), 2601-2613, (2020).
37. Ran, H., Tsutsumi, R., Araki, T. & Neel, B. G. Sticking It to Cancer with Molecular Glue for SHP2. *Cancer Cell*. **30** (2), 194-196, (2016).


**A** Normal Cells:





**B** Leukemias:






**C** Solid Tumors:











Name of Material/ Equipment	Company	Model or Catalog Number	Comments/Description
384-well gradient equipped thermocycler	Eppendorf AG	X50h	Sterile with lid
384-well low dead volume microplate Echo qualified	Beckman Coulter, Inc.	LP-0200	
6-well cell culture plates	Greiner Bio-One	657 160	
Antibiotic-Antimycotic (Anti Anti) 100 X	Thermo Fisher Scientific	15240-062	
Cell counter	Thermo Fisher Scientific	Countess II FL	
Dulbecco's Modified Eagle Medium 1X + GlutaMAX	Thermo Fisher Scientific	10566-016	500 mL
Echo acoustic liquid handler	Beckman Coulter, Inc.	Echo 550	
Electronic multichannel pipette	Thermo Fisher Scientific	E1 ClipTip	
Fetal bovine serum	Thermo Fisher Scientific	26140-079	500 mL
HEPES buffer	Thermo Fisher Scientific	15630-680	100 mL
InCell Pulse starter kit	Eurofins DiscoverX Corp.	94-4007	Components include EA bu
Microplate reader	Tecan Trading AG	Spark	
Single channel solution trough	Thermo Fisher Scientific	S253012005	
Sodium pyruvate	Thermo Fisher Scientific	11360-010	100 mM
Thermal microplate sealer	Agilent Technologies, Inc.	PlateLoc	
Transfection reagents	Polyplus Transfection	jetPRIME	
Trypan blue	Thermo Fisher Scientific	T10282	
TrypLE Express reagent	Thermo Fisher Scientific	12605-010	
Twin.tec 384 real-time PCR plates	Eppendorf AG	30132734	

ffer, lysis buffer, and substrate

**Lutz Tautz, Ph.D.**Research Associate Professor  
Cancer Metabolism & Signaling Networks Program  
NCI-Designated Cancer Center  
tautz@sbpdiscovery.org

May 4, 2020

**Re: Invited Manuscript Submission**

Dear Dr. Werth,

Please find enclosed our revised manuscript: "Assessing cellular target engagement by SHP2 (PTPN11) phosphatase inhibitors" by Lambert et al.

We thank the reviewers for their very positive reviews of the manuscript. In response to the comments by reviewer 1 we made the following changes (reviewer's comments in *blue italic* font):

*Major Concerns:*

*The table of materials at the end of the document is a mess. In its current form it is of no use. I presume this is an oversight or a formatting error and should be resolved. Some data is missing. The columns are not aligned correctly.*

We added additional information to the table of materials. We do not have control over the correct formatting of the table as it appears in the assembled PDF.

*Minor Concerns:*

*A small expansion of the section on data analysis would be helpful especially for the non-expert user. Explanation of terms such a V50 would make the protocol more accessible.*

We expanded the Data Analysis section and added an explanation of 'V50' as suggested.

*The statement "Assay development requires optimization of the signal window to assure reliable results are obtained." should be expanded upon to enable to reader to understand what type of optimization may be required. A list of what parameters may need to be varied would be helpful.*

To address this comment, we added the following new paragraph into the Discussion section:  
Assay development requires optimization of the chemiluminescent signal window to assure reliable results are obtained. To optimize the assay window, the most significant parameter is the formulation of the detection reagent master mix as described in the supplier's manual. This optimization is performed by systematically changing the EA reagent to substrate ratio in the master mix, while the lysis buffer component is held constant (four different conditions are usually sufficient for this measurement). A condition with zero EA reagent serves as the background. The assay is performed as described above, and the ratio of the observed signal to background (S/B) is calculated. Reliable results are obtained when the S/B ratio is >50. Master mix conditions that result in extraordinarily high signal are to be avoided, as they will result in depletion of the chemiluminescence substrate.

*Figure 3 is of limited value in its current form. I understand that the video may make this less of a problem but the pictures shown are of such low resolution that it is impossible to see what is attempted to be shown especially in the second step. A clearer flow diagram would be of more value.*

We have revised Figure 3. We assume that the low resolution of figures as they appear in the assembled PDF document will be mitigated during the JoVE production process. We did submit high-resolution figures.

We thank the editorial team for their comments and suggestions. As requested by the JoVE editorial team, we made the following changes:

**1) Proofreading:**

We proofread the manuscript to ensure that there are no spelling or grammatical errors. All changes were tracked with MS Word Track Changes.

**2) Protocol Detail:**

We made sure all necessary details are included in the protocol. We are unable to define the composition of EA reagent, lysis buffer, and substrate reagent as requested, as these are Eurofins DiscoverX proprietary reagents of undisclosed composition.

**3) Protocol Highlight:**

We revised the highlighted sections to ensure we highlight <2.75 pages of text.

**4) Discussion:**

In addition to the added paragraph in response to reviewer 1 (see above), we added the following new paragraph, which discusses the limitations of the assay:

*A potential limitation of the assay is its sensitivity. In our experience, inhibitors with at least a low micromolar potency in SHP2 phosphatase inhibition assays are required for producing measurable effects in the cellular thermal shift assay. As a general guideline, we suggest to first assess candidate compounds in in vitro PTS assays using recombinant SHP2<sup>36</sup>. Based on results from our ongoing SHP2 inhibitor discovery program, a compounds ability to shift the SHP2 melting temperature in vitro tracks well with its capacity to stabilize (or sometimes destabilize) the SHP2 protein in cells. Interestingly, the relative stabilization of SHP2-WT by SHP099-like allosteric inhibitors appears to be greater than that caused by equally potent SHP2 active site-directed inhibitors, likely reflecting the ability of the allosteric inhibitors to effectively stabilize a physiologically relevant conformation of the SHP2-WT protein.*

**5) Figure/Table Legends:**

We defined all error bars in the figure and table legends.

**6) References:**

We spelled out full journal names in the References section as requested.

**7) Commercial Language:**


In order to comply with JoVE's policies, we made the following changes as requested:

- Deleted "In Cell Pulse" from Figure 2.
- Deleted "Labcyte Echo" and "Tecan Spark" from Figure 3.
- Removed "Echo" from the manuscript.
- Deleted "InCell Pulse" from the manuscript.
- Deleted "GlutaMAX" from the manuscript.
- Deleted "TryLE" from the manuscript.
- Deleted "Countess" from the manuscript.
- Deleted "jetPRIME" from the manuscript.
- Deleted "Twin.tec 384" from the manuscript.
- Deleted "Agilent PlateLoc" from the manuscript.
- Deleted "X50h Mastercycler" from the manuscript.
- Deleted "TECAN Spark Multimode Microplate Reader" from the manuscript.

- Deleted company names from the manuscript, including Thermo-Fisher Scientific; Polylus, Illkirch, France; Graphpad Prism; Eppendorf; Greiner.

We hope that you will find the article with the included changes suitable for publication in JoVE, and we look forward to hearing from you.

Sincerely yours,

A handwritten signature in black ink, appearing to read 'Lutz Tautz', with a stylized, cursive script.

Lutz Tautz, Ph.D.

Figure 1 is a modified version we previously published in JBC. According to the JBC website, "Authors are allowed to do the following:

to use all or part of the work in compilations or other publications of the Authors' own commercial and noncommercial works (includes theses/dissertations), to use figures, photos, and tables created by them and contained in the work, ..." (<https://www.asbmb.org/journals-news/editorial-policies#copyright>)